Arsenic trioxide: A "successful poison" in patients with acute promyelocytic leukemia;Arsentrioxid: "ein erfolgreiches gift" bei patienten mit akuter promyelozytenleukämie

Deutsche Medizinische Wochenschrift

Volumn 132, Issue 7, 2007, Pages 330-336

  Lengfelder, Eva ^a   Schultheis, B ^a   Buchner T ^b   Hehlmann, R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Arsenic toxide; Promyelocytic leukemia

Indexed keywords

ARSENIC TRIOXIDE;

ACUTE PROMYELOCYTIC LEUKEMIA DIFFERENTIATION SYNDROME; APOPTOSIS; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CELL DIFFERENTIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; PROMYELOCYTIC LEUKEMIA; SURVIVAL RATE; SURVIVAL TIME;

EID: 33947168855     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-959329     Document Type: Article

References (51)

1. Au WY, Chim CS, Lie AK, Liang R, Kwong YL. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002; 117: 130-132
2. Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol 2001; 112: 783-786
3. Camacho LH, Soignet SL, Chanel S et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18: 2620-2625
4. Carmosino I, Latagliata R, Avvisati G et al. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 2004; 89: 615-617
5. Chen GQ, Shi XG, Tang W et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353
6. Chou WC, Hawkins AL, Barrett JF, Griffin CA, Dang CV. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 2001; 108: 1541-1547
7. De Botton S, Fawaz A, Chevret S et al. Autologous and allogeneic stem- cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005; 23: 120-126
8. Degos L, Dombret H, Chomienne C et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643-2653
9. Douer D, Hu W, Giralt S, Lill M, DiPersio J. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003; 8: 132-140
10. Douer D, Tollman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005; 23: 2396-2410
11. Doyle AC. Notes of a case of leukocythaemia. Lancet 1882; 119: 490
12. Estey E, Garcia-Manero G, Ferrajoli A et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107: 3469-3473
13. Forkner CE, Scott TF. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931; 97: 3-5
14. Frankel SR, Eardley A, Lauwers G, Weiss M, Jr. Warrell RP. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296
15. George B, Mathews V, Poonkuzhali B, Shaji RV, Srivasrava A, Chandy M. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia 2004; 18: 1587-1590
16. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17: 131-134
17. Helwig A, Klemm M, Schuttig R et al. Arsenic-induced APL differentiation in cerebrospinal fluid. Leuk Res 2006: Epub ahead of print
18. Jing Y, Wang L, Xia L et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264-269
19. Kai T, Kimura H, Shiga Y, Ogawa K, Sato H, Maruyama Y. Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy. Int J Hematol 2006; 83: 337-340
20. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide-and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol 2001; 66: 274-279
21. Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003; 97: 2218-2224
22. Lengfelder E, Gnad U, Büchner T, Hehlmann R. Treatment of relapsed acute promyelocytic leukemia. Onkologie 2003; 26: 373-379
23. Lengfelder E, Hehlmann R, Büchner T. Aktuelle Therapiekonzepte bei akuter Promyelozytenleukämie. Dtsch Med Wochenschr 2001; 126: 1073-1079
24. Lengfelder E, Saussele S, Weisser A, Büchner T, Hehlmann R. Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol 2005; 56: 261-274
25. Leoni F, Gianfaldoni G, Annunziata M et al. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica 2002; 87: 485-489
26. Lu DP, Qiu JY, Jiang B et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 3136-3143
27. Mathews V, George B, Lakshmi KM et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627-2632
28. Jr. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903
29. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324
30. Ohnishi K, Yoshida H, Shigeno K et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16: 617-622
31. Raffoux E, Rousselot P, Poupon J et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2326-2334
32. Roboz GJ, Dias S, Lam G et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530
33. Sanz MA, Arcese W, de la Rubia J et al. Stem cell transplantation for acute promyelocytic leukemia in the ATRA era: A survey of the European Blood and Marrow Transplantation Group. Blood 2000; 96: 522a
34. Sanz MA, Fenaux P, LoCoco F. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90: 1231-1235
35. Shen Y, Shen ZX, Yan H et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 2001; 15: 735-741
36. Shen ZX, Chen GQ, Ni JH et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360
37. Shen ZX, Shi ZZ, Fang J et al. All-trans retinoic acid/ As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004; 101: 5328-5335
38. Shigeno K, Naito K, Sahara N et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005; 82: 224-229
39. Siu CW, Au WY, Yung C et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood 2006; 108: 103-106
40. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860
41. Soignet SL, Maslak P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348
42. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-767
43. Thomas X, Dombret H, Cordonnier C et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia. Leukemia 2000; 14: 1006-1013
44. Thomas X, Pigneux A, Raffoux E, Huguet F, Caillot D, Fenaux P. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia. Haematologica 2006; 91: 996-997
45. Trisenox. Summary of Product Characteristics 2002; Cell Therapeutics Europe, 5
46. Tsimberidou AM, Estey E, Whitman GJ et al. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 2004; 28: 991-994
47. Unnikrishnan D, Dutcher JP, Varshneya N et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514-1516
48. Wang Z, Zhou J, Lu X, Gong Z, Le XC. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 2004; 17: 95-103
49. Westervelt P, Brown RA, Adkins DR et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98: 266-271
50. Zhang P, Wang S, Hu L et al. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide - an analysis of 242 cases. Zhonghua Xue Ye Xue Za Zhi 2000; 21: 67-70
51. Zhu J, Koken MH, Quignon F et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997; 94: 3978-3983